REGULATORY
Japan to Simplify Screening for Third-Party Use of Highly Anonymous NDB Data
A Japanese health ministry panel on March 6 endorsed a draft proposal to update the flow for providing data on the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB) to third parties. In principle, data…
To read the full story
Related Article
- MHLW Panel OKs Changes to Guidelines for Using NDB, Anonymized Medical Data
September 11, 2023
REGULATORY
- DPP Calls for End to Off-Year Drug Price Cuts, Chuikyo Reform
June 15, 2026
- Pharma Wages Multi-Front Lobbying amid Push for Leaner Honebuto
June 12, 2026
- Many Approved AGs Remain Unlisted Despite Final Pre-Reform Opportunity
June 12, 2026
- iPark CEO Calls for National AI Drug Discovery Platform at LDP Hearing
June 12, 2026
- MHLW Official Urges Proper IRB Selection under New GCP Rules
June 12, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





